JOHNSON & JOHNSON Q2 2025 Filing

Filed July 22, 2025

Portfolio Value

$334.1B

Holdings

20

Report Date

Q2 2025

Filing Type

13F-HR

All Holdings (20 positions)

#StockSharesValue% PortfolioType
1
PTGXProtagonist Therapeutics Inc.
2,449,183$136.4B40.83%
2
MGTXMeiraGTx Holdings plc
6,641,064$43.9B13.14%
3
RAPPRapport Therapeutics, Inc.
2,498,051$28.6B8.55%
4
LEGNLegend Biotech Corporation
814,586$28.2B8.44%
5
NBTXNanobiotix S.A.
5,623,816$25.5B7.62%
6
CVRXCVRx, Inc.
4,103,430$23.9B7.15%
7
PRCTProcept BioRobotics Corporation
357,939$20.4B6.10%
8
CTNMContineum Therapeutics Inc.
1,979,173$8.1B2.43%
9
XNCRXencor, Inc.
748,062$6.1B1.82%
10
ARWRArrowhead Pharmaceuticals, Inc.
247,598$4.0B1.19%
11
FATEFate Therapeutics, Inc.
3,379,064$3.5B1.05%
12
NMRANeumora Therapeutics, Inc.
1,849,445$1.4B0.42%
13
RLYBRallybio Corporation
3,636,363$1.2B0.36%
14
VORVor Biopharma, Inc.
1,074,658$1.1B0.34%
15
NNOXNano-X Imaging Ltd.
158,852$830.8M0.25%
16
FLBStandard BioTools Inc
311,967$371.2M0.11%
17
LYELLyell Immunopharma Inc.
41,165$368.0M0.11%
18
TORCEURAdicet Bio, Inc.
364,472$228.0M0.07%
19
PHGEBiomX Inc.
96,866$42.6M0.01%
20
SENS1GBPSenseonics Holdings, Inc.
54,621$27.0M0.01%